Bioprocessing Equipment Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2026 - 2035

The Global Bioprocessing Equipment Market was valued at USD 48.1 billion in 2025 and is estimated to grow at a CAGR of 12.3% to reach USD 152.2 billion by 2035.

The market continues to expand as biopharmaceutical manufacturers increase investments in advanced production technologies to improve efficiency, scalability, and product quality. Growing adoption of single-use bioprocessing systems, increasing demand for biologics and biosimilars, and the rapid commercialization of cell and gene therapies are creating strong demand for sophisticated bioprocessing equipment. In addition, the expansion of contract manufacturing organizations (CMOs) and contract research organizations (CROs) is accelerating equipment procurement and encouraging continuous upgrades of manufacturing infrastructure. Companies are increasingly investing in automated production platforms, process optimization technologies, and high-performance equipment to improve manufacturing flexibility while maintaining regulatory compliance. Continuous advancements in bioprocess engineering, increasing research activities, and growing investments in next-generation therapeutic manufacturing are further strengthening the industry's outlook. Leading participants, including Danaher, Sartorius AG, Merck, Thermo Fisher Scientific, and Repligen Corporation, continue to reinforce their competitive position through sustained product innovation, research and development investments, global business expansion, and strategic collaborations with healthcare organizations and life science institutions.

The bioreactors segment captured USD 13.3 billion in 2025. Bioreactors continue to represent one of the most essential components of modern bioprocessing because they provide highly controlled environments for cultivating microorganisms, mammalian cells, and other biological materials required for pharmaceutical manufacturing. Growing production of biologics, biosimilars, vaccines, and advanced therapeutic products is driving sustained demand for high-performance bioreactor systems. Continuous improvements in bioreactor design, automation capabilities, process monitoring technologies, and manufacturing efficiency are further supporting segment growth while enabling manufacturers to increase production capacity and maintain consistent product quality.

The biopharmaceutical and pharmaceutical companies segment accounted for 63.1% share in 2025. These organizations continue to invest heavily in advanced manufacturing technologies to strengthen the production of biologics, vaccines, biosimilars, and emerging therapeutic products. Increasing emphasis on manufacturing efficiency, process standardization, regulatory compliance, and production scalability is encouraging widespread adoption of advanced bioprocessing equipment across pharmaceutical manufacturing facilities. Furthermore, continuous expansion of research and development activities, increasing commercialization of innovative therapies, and growing investments in modern manufacturing infrastructure are expected to sustain strong demand from this end-user segment throughout the forecast period.

North America Bioprocessing Equipment Market held a 38% share in 2025. The region continues to demonstrate strong growth, supported by its well-established biopharmaceutical manufacturing ecosystem, advanced healthcare infrastructure, and increasing investments in biotechnology research and development. Favorable government initiatives, expanding production of biologics and advanced therapeutics, and the growing prevalence of chronic diseases are accelerating the adoption of modern bioprocessing equipment across the region. In addition, continuous technological advancements in bioprocessing systems, increasing demand for automated and single-use manufacturing solutions, and the presence of leading pharmaceutical and biotechnology companies are creating significant growth opportunities. Ongoing investments in manufacturing capacity expansion, research facilities, and next-generation bioprocessing technologies are expected to further strengthen North America's leadership in the Bioprocessing Equipment Market throughout the forecast period.

Major companies operating in the global bioprocessing equipment market include ABEC Inc., Cellexus Ltd., Danaher, Distek Inc., Eppendorf AG, Getinge AB, Lonza Group, Merck, PBS Biotech Inc., Pierre Guerin Technologies (SPX Flow), Repligen Corporation, Sartorius AG, Single Use Support GmbH, Solaris Biotech (Donaldson), and Thermo Fisher Scientific. Companies operating in the global bioprocessing equipment market are strengthening their competitive position by investing extensively in product innovation, advanced manufacturing technologies, and research and development initiatives. Leading manufacturers are expanding their portfolios with highly automated, scalable, and single-use bioprocessing solutions that improve production efficiency while reducing operational complexity. Strategic partnerships with pharmaceutical companies, biotechnology firms, CMOs, and research institutions are helping organizations strengthen customer relationships and expand their global market presence. Businesses are also investing in digital process monitoring, automation technologies, and smart manufacturing platforms to enhance operational performance and improve process consistency. In addition, companies are expanding production capacity, strengthening global distribution networks, improving technical support services, and developing customized bioprocessing solutions to reinforce their market foothold, enhance competitiveness, and capitalize on the growing demand across the global bioprocessing equipment market.